Detailansicht

Wissensnetz

Person

Juliane S. Walz (1985-)

Internistin

Name	Juliane S. Walz
Zeit	1985- (Lebensdaten)
Ort	Calw (Geburtsort) Deutschland
Geschlecht	weiblich
Akademischer Grad bzw. Titel	Dr. med. (Univ. Tübingen) (2011)
Beruf	Internistin (charakteristischer Beruf)
Variante	Juliane Sarah Walz Juliane Sarah Stickel (Geburtsname) (früherer Name) J.S. Walz
Weitere Angaben	Habilitation Fach Innere Medizin, Universität Tübingen, Fachärztin für Innere Medizin, Hämatologie und Onkologie
Datensatztyp	Person
GND-Nummer	143596403
Datensatz-ID	143596403
Beteiligt an alle anzeigen HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy Multi-omics analysis of overexpressed tumor-associated proteins: gene expression, immunopeptide presentation, and antibody response in oropharyngeal squamous cell carcinoma, with a focus on cancer-testis antigens Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease A T-cell antigen atlas for meningioma: novel options for immunotherapy DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts Immune surveillance of acute myeloid leukemia is mediated by HLA-presented antigens on leukemia progenitor cells The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma Tumorimpfstoffe SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function Tumorimpfstoffe Tumorvakzinierung –Strategien und Timing Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A02:01‑restricted T cell epitopes, which are presented and recognized in vivo Tumorvakzinierung –Strategien und Timing NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies Designing a SARS-CoV-2 T-cell-inducing vaccine for high-risk patient groups Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition Cancer testis antigen Cyclin A1 harbors several HLA-A02:01-restricted T cell epitopes, which are presented and recognized in vivo Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma—a long-term follow-up single center experience Identification of HCMV-derived T cell epitopes in seropositive individuals through viral deletion models A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer The role of autologous stem cell transplantation in peripheral T cell lymphoma: a long-term follow-up single-center experience The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy Immunopeptidom-Analyse hämatologischer Neoplasien : Charakterisierung neuer Leukämie-assoziierter Antigene für eine Peptid-basierte Immuntherapie A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy Qualitative und quantitative Analyse und Vergleich von Tumorantigenen und HLA-Klasse-I-Liganden in Primärtumoren und Metastasen des Nierenzellkarzinoms

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy

Multi-omics analysis of overexpressed tumor-associated proteins: gene expression, immunopeptide presentation, and antibody response in oropharyngeal squamous cell carcinoma, with a focus on cancer-testis antigens

Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors

TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification

DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

A T-cell antigen atlas for meningioma: novel options for immunotherapy

DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts

Immune surveillance of acute myeloid leukemia is mediated by HLA-presented antigens on leukemia progenitor cells

The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Tumorimpfstoffe

SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function

Tumorimpfstoffe

Tumorvakzinierung –Strategien und Timing

Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivo

Tumorvakzinierung –Strategien und Timing

NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies

Designing a SARS-CoV-2 T-cell-inducing vaccine for high-risk patient groups

Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo

Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma—a long-term follow-up single center experience

Identification of HCMV-derived T cell epitopes in seropositive individuals through viral deletion models

A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

The role of autologous stem cell transplantation in peripheral T cell lymphoma: a long-term follow-up single-center experience

The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy

Immunopeptidom-Analyse hämatologischer Neoplasien : Charakterisierung neuer Leukämie-assoziierter Antigene für eine Peptid-basierte Immuntherapie

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

Qualitative und quantitative Analyse und Vergleich von Tumorantigenen und HLA-Klasse-I-Liganden in Primärtumoren und Metastasen des Nierenzellkarzinoms